{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:04:05Z","timestamp":1764306245643,"version":"3.46.0"},"reference-count":123,"publisher":"Open Exploration Publishing","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Explor Med"],"accepted":{"date-parts":[[2025,10,19]]},"abstract":"<jats:p xml:lang=\"en\">Cancer immunotherapies have become mainstream, targeting tumor elimination via various mechanisms, albeit with varied effectiveness. Here, we review briefly the current landscape of cancer immunotherapies and the central role of human leukocyte antigen (HLA) in them. We then propose a new kind of immunotherapy for solid tumors, where the key is the involvement of antigens and antibodies unrelated to the tumor itself. In this approach, we consider the tumor as akin to a transplanted organ, which can be rejected by two different mechanisms of incompatibility. The first involves the intra-tumor administration of mRNA blueprints of incompatible (to the patient) HLA proteins, leading to their synthesis and, hopefully, elicitation of an anti-tumor immune reaction, assuming immunocompetency. The second therapy involves the direct, intra-tumor administration of anti-A\/B\/H blood group antibodies lining the blood and lymph vessels of the tumor. In organ transplantation, AB incompatibility leads to organ rejection, and the same effect would be expected when anti-A\/B\/H antibodies (depending on the patient\u2019s ABO group) are injected into the tumor. Notably, the anti-tumor effect by the preformed anti-blood group antibodies is complement-mediated and should not be affected by tumor immunoevasion. This proposed cancer immunotherapy aimed at promoting tumor rejection via antigen incompatibility offers a novel cancer treatment approach that warrants further investigation.<\/jats:p>","DOI":"10.37349\/emed.2025.1001375","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T04:51:56Z","timestamp":1764305516000},"update-policy":"https:\/\/doi.org\/10.37349\/open_exploration_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Solid tumor rejection using personalized incompatible human leukocyte antigen (HLA) and blood group ABH antigens"],"prefix":"10.37349","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4412-725X","authenticated-orcid":false,"given":"Apostolos P.","family":"Georgopoulos","sequence":"first","affiliation":[{"name":"The HLA Cancer Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN 55417, USA; Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN 55455, USA; Institute for Health Informatics, University of Minnesota Medical School, Minneapolis, MN 55455, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9021-0690","authenticated-orcid":false,"given":"Lisa M.","family":"James","sequence":"additional","affiliation":[{"name":"The HLA Cancer Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN 55417, USA; Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN 55455, USA; Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN 55455, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21850","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"5614","DOI":"10.62347\/MWNZ5609","article-title":"Advancing precision and personalized breast cancer treatment through multi-omics technologies","volume":"14","author":"Zhang","year":"2024","journal-title":"Am J Cancer Res"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Scheffel TB, editor. James, LM. HLA-based Immunotherapy for Cancer","DOI":"10.5772\/intechopen.1011836"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cells14181430","article-title":"mRNA Multipeptide-HLA Class II Immunotherapy for Melanoma","volume":"14","author":"Georgopoulos","year":"2025","journal-title":"Cells"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/tan.13811","article-title":"Common, intermediate and well-documented HLA alleles in world populations: CIWD version 3.0.0","volume":"95","author":"Hurley","year":"2020","journal-title":"HLA"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nri3754","article-title":"Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell?","volume":"14","author":"Kambayashi","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/BF02899573","article-title":"Expression of MHC class II antigens in human lung cancer cells","volume":"60","author":"Kamma","year":"1991","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.lungcan.2017.07.030","article-title":"MHC class II expression in lung cancer","volume":"112","author":"He","year":"2017","journal-title":"Lung Cancer"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/CMR.0000000000001022","article-title":"MHC class II: a predictor of outcome in melanoma treated with immune checkpoint inhibitors","volume":"35","author":"Amrane","year":"2025","journal-title":"Melanoma Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/bs.ai.2023.08.002","article-title":"The show and tell of cross-presentation","volume":"159","author":"Blander","year":"2023","journal-title":"Adv Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1146\/annurev-immunol-032712-095910","article-title":"Pathways of antigen processing","volume":"31","author":"Blum","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","article-title":"A guide to antigen processing and presentation","volume":"22","author":"Pishesha","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nri3818","article-title":"The ins and outs of MHC class II-mediated antigen processing and presentation","volume":"15","author":"Roche","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/jmr.300060204","article-title":"MHC class I\/peptide interactions: binding specificity and kinetics","volume":"6","author":"Margulies","year":"1993","journal-title":"J Mol Recognit"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/hep.24299","article-title":"Electrostatic modifications of the human leukocyte antigen-DR P9 peptide-binding pocket and susceptibility to primary sclerosing cholangitis","volume":"53","author":"Hov","year":"2011","journal-title":"Hepatology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S1877-1173(10)92003-6","article-title":"The origin and role of MHC class I-associated self-peptides","volume":"92","author":"Perreault","year":"2010","journal-title":"Prog Mol Biol Transl Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/345615a0","article-title":"Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding","volume":"345","author":"Roche","year":"1990","journal-title":"Nature"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltaf002","article-title":"Imaging antigen processing and presentation in cancer","volume":"5","author":"Lau","year":"2025","journal-title":"Immunother Adv"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1540431","article-title":"Unlocking the secrets of the immunopeptidome: MHC molecules, ncRNA peptides, and vesicles in immune response","volume":"16","author":"Balakrishnan","year":"2025","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1158\/2326-6066.CIR-24-0320","article-title":"Alternate MHC I Antigen Presentation Pathways Allow CD8+ T-cell Recognition and Killing of Cancer Cells in the Absence of \u03b22M or TAP","volume":"13","author":"Cruz","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25021205","article-title":"Extracellular Vesicles and Immunity: At the Crossroads of Cell Communication","volume":"25","author":"Aloi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.bmc.2011.06.039","article-title":"A bright approach to the immunoproteasome: development of LMP2\/\u03b21i-specific imaging probes","volume":"20","author":"Carmony","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/cbic.201200307","article-title":"Activity-based near-infrared fluorescent probe for LMP7: a chemical proteomics tool for the immunoproteasome in living cells","volume":"13","author":"Sharma","year":"2012","journal-title":"Chembiochem"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/14728222.2020.1751821","article-title":"ERAP1: a potential therapeutic target for a myriad of diseases","volume":"24","author":"Reeves","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.bmc.2010.10.028","article-title":"Functional in vivo imaging of cysteine cathepsin activity in murine model of inflammation","volume":"19","author":"Cagli\u010d","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.2967\/jnumed.121.263151","article-title":"Dynamic Tumor-Specific MHC-II Immuno-PET Predicts the Efficacy of Checkpoint Inhibitor Immunotherapy in Melanoma","volume":"63","author":"Yang","year":"2022","journal-title":"J Nucl Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/s41590-018-0162-7","article-title":"TCRs are randomly distributed on the plasma membrane of resting antigen-experienced T cells","volume":"19","author":"Rossboth","year":"2018","journal-title":"Nat Immunol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"7201","DOI":"10.1073\/pnas.1512331113","article-title":"Superresolution imaging reveals nanometer- and micrometer-scale spatial distributions of T-cell receptors in lymph nodes","volume":"113","author":"Hu","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1158\/0008-5472.CAN-15-2784","article-title":"Immuno-PET Imaging of Engineered Human T Cells in Tumors","volume":"76","author":"Mall","year":"2016","journal-title":"Cancer Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2022.100230","article-title":"MHC Class I Immunopeptidome: Past, Present, and Future","volume":"21","author":"Yewdell","year":"2022","journal-title":"Mol Cell Proteomics"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.4049\/jimmunol.157.5.1823","article-title":"Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules?","volume":"157","author":"Yewdell","year":"1996","journal-title":"J Immunol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-018-0794-7","article-title":"The translation of non-canonical open reading frames controls mucosal immunity","volume":"564","author":"Jackson","year":"2018","journal-title":"Nature"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36826-0","article-title":"Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response","volume":"14","author":"Barczak","year":"2023","journal-title":"Nat Commun"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2020.04.006","article-title":"Translatable circRNAs and lncRNAs: Driving mechanisms and functions of their translation products","volume":"483","author":"Kong","year":"2020","journal-title":"Cancer Lett"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00018-016-2409-5","article-title":"A researcher\u2019s guide to the galaxy of IRESs","volume":"74","author":"Terenin","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10081865","article-title":"Internal Ribosome Entry Site (IRES)-Mediated Translation and Its Potential for Novel mRNA-Based Therapy Development","volume":"10","author":"Marques","year":"2022","journal-title":"Biomedicines"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/imcb.12839","article-title":"Antigen presentation of post-translationally modified peptides in major histocompatibility complexes","volume":"103","author":"de Wit","year":"2025","journal-title":"Immunol Cell Biol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF03401948","article-title":"The transporter associated with antigen processing (TAP): structural integrity, expression, function, and its clinical relevance","volume":"7","author":"Ritz","year":"2001","journal-title":"Mol Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1073\/pnas.92.4.1218","article-title":"The three-dimensional structure of a class I major histocompatibility complex molecule missing the alpha 3 domain of the heavy chain","volume":"92","author":"Collins","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/(SICI)1097-0282(1997)43:4<281::AID-BIP3>3.0.CO;2-R","article-title":"Peptide binding by class I and class II MHC molecules","volume":"43","author":"Batalia","year":"1997","journal-title":"Biopolymers"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/j.1365-2567.2003.01738.x","article-title":"The MHC class I antigen presentation pathway: strategies for viral immune evasion","volume":"110","author":"Hewitt","year":"2003","journal-title":"Immunology"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0965-7","article-title":"Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance","volume":"18","author":"Maacha","year":"2019","journal-title":"Mol Cancer"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41590-021-00899-0","article-title":"Extracellular vesicles in immunomodulation and tumor progression","volume":"22","author":"Marar","year":"2021","journal-title":"Nat Immunol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/s1074-7613(00)80483-5","article-title":"Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response","volume":"4","author":"Sykulev","year":"1996","journal-title":"Immunity"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nature01076","article-title":"Direct observation of ligand recognition by T cells","volume":"419","author":"Irvine","year":"2002","journal-title":"Nature"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217432","article-title":"Mechanisms of low MHC I expression and strategies for targeting MHC I with small molecules in cancer immunotherapy","volume":"611","author":"Kong","year":"2024","journal-title":"Cancer Lett"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-3-030-17864-2_3","article-title":"HLA Class-I Expression and Cancer Immunotherapy","volume":"1151","author":"Garrido","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/carcin\/22.10.1615","article-title":"DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas","volume":"22","author":"Nie","year":"2001","journal-title":"Carcinogenesis"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s13277-010-0054-4","article-title":"Downregulation of tapasin expression in primary human oral squamous cell carcinoma: association with clinical outcome","volume":"31","author":"Jiang","year":"2010","journal-title":"Tumour Biol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1084\/jem.179.1.335","article-title":"Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas","volume":"179","author":"Cromme","year":"1994","journal-title":"J Exp Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00432-022-04493-1","article-title":"HLA and tumour immunology: immune escape, immunotherapy and immune-related adverse events","volume":"149","author":"Jiang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.jaci.2018.02.042","article-title":"Immune checkpoint blockade therapy","volume":"142","author":"Wieder","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.trecan.2024.06.003","article-title":"Next-generation cancer vaccines and emerging immunotherapy combinations","volume":"10","author":"Brandenburg","year":"2024","journal-title":"Trends Cancer"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2023.100631","article-title":"The NLR member CIITA: Master controller of adaptive and intrinsic immunity and unexpected tool in cancer immunotherapy","volume":"46","author":"Forlani","year":"2023","journal-title":"Biomed J"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics9020059","article-title":"Expressions of HLA Class II Genes in Cutaneous Melanoma Were Associated with Clinical Outcome: Bioinformatics Approaches and Systematic Analysis of Public Microarray and RNA-Seq Datasets","volume":"9","author":"Chen","year":"2019","journal-title":"Diagnostics (Basel)"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-3-030-17864-2_4","article-title":"HLA Class-II Expression in Human Tumors","volume":"1151","author":"Garrido","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10582","article-title":"Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy","volume":"7","author":"Johnson","year":"2016","journal-title":"Nat Commun"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci Transl Med"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182786","article-title":"Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling","volume":"12","author":"Park","year":"2017","journal-title":"PLoS One"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1158\/2326-6066.CIR-15-0243","article-title":"Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes","volume":"4","author":"Forero","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061660","article-title":"Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process","volume":"12","author":"Feola","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.semcancer.2021.04.016","article-title":"Cancer\/testis antigens: from serology to mRNA cancer vaccine","volume":"76","author":"Fan","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061779","article-title":"The Melanoma-Associated Antigen Family A (MAGE-A): A Promising Target for Cancer Immunotherapy?","volume":"15","author":"Alsalloum","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat Cancer"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.3390\/cells12242837","article-title":"Therapeutic Monoclonal Antibodies against Cancer: Present and Future","volume":"12","author":"Delgado","year":"2023","journal-title":"Cells"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1172\/JCI80008","article-title":"Tumor neoantigens: building a framework for personalized cancer immunotherapy","volume":"125","author":"Gubin","year":"2015","journal-title":"J Clin Invest"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.672356","article-title":"Neoantigen: A New Breakthrough in Tumor Immunotherapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/biologics3040017","article-title":"Neoantigens: The Novel Precision Cancer Immunotherapy","volume":"3","author":"Zhang","year":"2023","journal-title":"Biologics"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.crbiot.2024.100177","article-title":"The landscape of neoantigens and its clinical applications: From immunobiology to cancer vaccines","volume":"7","author":"Chakraborty","year":"2024","journal-title":"Curr Res Biotechnol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0140-6736(25)00553-7","article-title":"Cancer vaccines and the future of immunotherapy","volume":"406","author":"Pail","year":"2025","journal-title":"Lancet"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1158\/2159-8290.CD-17-1418","article-title":"Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma","volume":"8","author":"Kalaora","year":"2018","journal-title":"Cancer Discov"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13404","article-title":"Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry","volume":"7","author":"Bassani-Sternberg","year":"2016","journal-title":"Nat Commun"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"23662","DOI":"10.1073\/pnas.1906026116","article-title":"Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens","volume":"116","author":"Linette","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.836821","article-title":"Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation","volume":"12","author":"Borden","year":"2022","journal-title":"Front Oncol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70020","article-title":"NY-ESO-1 antigen: A promising frontier in cancer immunotherapy","volume":"14","author":"Alsalloum","year":"2024","journal-title":"Clin Transl Med"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.3747\/co.27.5223","article-title":"A review of cancer immunotherapy: from the past, to the present, to the future","volume":"27","author":"Esfahani","year":"2020","journal-title":"Curr Oncol"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.961805","article-title":"Clinical cancer immunotherapy: Current progress and prospects","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.3390\/antib9030034","article-title":"Monoclonal Antibodies in Cancer Therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune Checkpoint Inhibitors in Cancer Therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1080\/21645515.2018.1508624","article-title":"Anti-CD20 monoclonal antibodies: reviewing a revolution","volume":"14","author":"Casan","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","year":"2025","journal-title":"Br J Cancer"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03231-z","article-title":"CAR-T and cellular gene therapies are too expensive","volume":"30","author":"Dropuli\u0107","year":"2024","journal-title":"Nat Med"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1177\/1533033819831068","article-title":"The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review","volume":"18","author":"Zhang","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0812-8","article-title":"Targeting cancers through TCR-peptide\/MHC interactions","volume":"12","author":"He","year":"2019","journal-title":"J Hematol Oncol"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690499","article-title":"Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer","volume":"12","author":"Kumar","year":"2021","journal-title":"Front Immunol"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11111633","article-title":"Recent Advances in Cancer Immunotherapy with a Focus on FDA-Approved Vaccines and Neoantigen-Based Vaccines","volume":"11","author":"Hargrave","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"7277","DOI":"10.1021\/acsomega.3c06501","article-title":"Revolutionizing Cancer Treatment: Unleashing the Power of Viral Vaccines, Monoclonal Antibodies, and Proteolysis-Targeting Chimeras in the New Era of Immunotherapy","volume":"9","author":"Mohite","year":"2024","journal-title":"ACS Omega"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2024.101324","article-title":"Cancer vaccines: Target antigens, vaccine platforms and preclinical models","volume":"101","author":"Ruzzi","year":"2025","journal-title":"Mol Aspects Med"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","article-title":"Recent advances in therapeutic cancer vaccines","volume":"25","author":"Zaidi","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1115641","article-title":"First oncolytic virus approved for melanoma immunotherapy","volume":"5","author":"Pol","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01670-w","article-title":"Cancer vaccines: current status and future directions","volume":"18","author":"Zhou","year":"2025","journal-title":"J Hematol Oncol"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13025","article-title":"Peptide-based therapeutic cancer vaccine: Current trends in clinical application","volume":"54","author":"Liu","year":"2021","journal-title":"Cell Prolif"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1210044","article-title":"Peptide-based vaccine for cancer therapies","volume":"14","author":"Buonaguro","year":"2023","journal-title":"Front Immunol"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-024-01102-w","article-title":"Advances in nucleic acid-based cancer vaccines","volume":"32","author":"Liao","year":"2025","journal-title":"J Biomed Sci"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.11.015","article-title":"Clinical advances of mRNA vaccines for cancer immunotherapy","volume":"6","author":"Yaremenko","year":"2025","journal-title":"Med"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1038\/s44276-023-00017-7","article-title":"Direct administration of human leucocyte antigen (dHLA) molecules into tumour sites: proposal for a new immunotherapy for cancer","volume":"1","author":"Georgopoulos","year":"2023","journal-title":"BJC Rep"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1177\/11769351241274160","article-title":"Nine Human Leukocyte Antigen (HLA) Class I Alleles are Omnipotent Against 11 Antigens Expressed in Melanoma Tumors","volume":"23","author":"Georgopoulos","year":"2024","journal-title":"Cancer Inform"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1399-0039.2006.00721.x","article-title":"ABO blood group and related antigens, natural antibodies and transplantation","volume":"68","author":"Milland","year":"2006","journal-title":"Tissue Antigens"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"Lodermeier M, Rahorst L. Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects. pp. 111\u20136.","DOI":"10.1016\/B978-0-323-96014-4.00097-5"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"13268","DOI":"10.1073\/pnas.0404740101","article-title":"Comparative immunopeptidomics of humans and their pathogens","volume":"101","author":"Istrail","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1046\/j.1537-2995.1998.381098440863.x","article-title":"The histo-blood group ABO system and tissue transplantation","volume":"38","author":"Eastlund","year":"1998","journal-title":"Transfusion"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1084\/jem.115.5.977","article-title":"The histological distribution of the blood group substances in man as disclosed by immunofluorescence: II. The H antigen and its relation to A and B antigens","volume":"115","author":"Szulman","year":"1962","journal-title":"J Exp Med"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00505","article-title":"Vascular endothelium as a target of immune response in renal transplant rejection","volume":"5","author":"Piotti","year":"2014","journal-title":"Front Immunol"},{"key":"ref117","first-page":"83","article-title":"Acute Rejection, Kidney Allograft Function, and Graft Survival in Patients with Circulating Pre-Transplant IgG Antibodies Directed Against Donor HLA-A, -B, or -C Locus Determined Antigens","volume":"32","author":"Abuhelaiqa","year":"2016","journal-title":"Clin Transpl"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/iju.14109","article-title":"Latest insights on ABO-incompatible living-donor renal transplantation","volume":"27","author":"Uchida","year":"2020","journal-title":"Int J Urol"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10585-024-10288-0","article-title":"Cancer metastasis through the lymphatic versus blood vessels","volume":"41","author":"Leong","year":"2024","journal-title":"Clin Exp Metastasis"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-95794-x","article-title":"ABO blood group antigen therapy: a potential new strategy against solid tumors","volume":"11","author":"Luo","year":"2021","journal-title":"Sci Rep"},{"key":"ref121","doi-asserted-by":"publisher","unstructured":"Hasani F, Sadat Hosseini S. New Updates in Tumor Microenvironment","DOI":"10.5772\/intechopen.1003886"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMsb2300232","article-title":"Immune Checkpoint Inhibitors\u2014The Need for Innovation","volume":"388","author":"Johnson","year":"2023","journal-title":"N Engl J Med"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1523693","article-title":"Prodrug-based bispecific antibodies for cancer therapy: advances and future directions","volume":"16","author":"Ai","year":"2025","journal-title":"Front Immunol"}],"container-title":["Exploration of Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T04:51:58Z","timestamp":1764305518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.explorationpub.com\/Journals\/em\/Article\/1001375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":123,"URL":"https:\/\/doi.org\/10.37349\/emed.2025.1001375","archive":["Portico","Portico"],"relation":{},"ISSN":["2692-3106"],"issn-type":[{"value":"2692-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"2025-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-28","order":2,"name":"published","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1001375"}}